Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

Go back to Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

Forte Biosciences (FBRX) Tops Q1 EPS by 16c

May 10, 2021 4:56 PM EDT

Forte Biosciences (NASDAQ: FBRX) reported Q1 EPS of ($0.36), $0.16 better than the analyst estimate of ($0.52).

Forte has continued to make excellent progress in the fist quarter of 2021. As we have previously highlighted, our randomized clinical trial of FB-401 in atopic dermatitis patients 2 years of age... More